Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta thalassemia disease - Archive ouverte HAL Access content directly
Journal Articles European Journal of Pharmacology Year : 2019

Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta thalassemia disease

, , (1) , , (2) , (3) , (4) , (5) , (2)
1
2
3
4
5

Dates and versions

mnhn-02866469 , version 1 (12-06-2020)

Identifiers

Cite

Mohammad Ali Khosravi, Maryam Abbasalipour, Jean-Paul Concordet, Johannes Vom Berg, Sirous Zeinali, et al.. Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta thalassemia disease. European Journal of Pharmacology, 2019, 854, pp.398-405. ⟨10.1016/j.ejphar.2019.04.042⟩. ⟨mnhn-02866469⟩
32 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More